ライフサイエンスコーパス: pretherapy

1 enewal of clonal specificities compared with pretherapy.

2 IAFs outside the thyroid bed not detected on pretherapy ( 123)I scans in 21 (19%, P < .001) of 108 pa

3 Each patient had undergone a pretherapy ( 123)I whole-body scan followed by a postthe

4 ng occurred in 10% of patients compared with pretherapy ( 123)I whole-body scintigraphy.

5 and 114 sites and/or organs were involved on pretherapy (18)F-FDG PET and CT scans, respectively.

6 All patients underwent dual-phase pretherapy (18)F-FDG PET for which, after the intravenou

7 agnostic CT scan or on the CT component of a pretherapy (18)F-FDG PET/CT scan, whichever was obtained

8 easuring the response of patients with a low pretherapy (18)F-FDG uptake.

9 Pretherapy (60)Cu-ATSM PET provides clinically relevant

10 Furthermore, pretherapy analysis of tumor DNA mismatch repair and, pa

11 Tumor biopsies pretherapy and 2 and 4 weeks after gene injection were o

12 CF is associated with periodontitis severity pretherapy and extent of therapeutic response post-thera

13 In this study, pretherapy and follow-up (124)I PET/CT data on BMs from

14 Pretherapy and follow-up imaging are important for stagi

15 For all lesions seen on pretherapy and midtherapy scans, the correlation was 0.9

16 The surface antigen expression profiles of pretherapy and postrelapse LSCs were determined for publ

17 tly observed in leukemic blast cells in both pretherapy and relapsed samples, consistent with MDR as

18 analysis, respectively, in biopsies from the pretherapy and surgical specimens.

19 led in the Abbott M97-720 trial at baseline (pretherapy) and weeks 60 to 384 by using an HIV-1 RNA as

20 inical attachment levels (CAL) were assessed pretherapy, and at 3 months following completion of acti

21 herapy, or rPFS for patients with or without pretherapy AR-V7-positive CTCs treated with a taxane.

22 differences in substrate specificity between pretherapy B and AE proteases.

23 Structural analysis of atazanavir bound to a pretherapy B protease showed that the ability of atazana

24 D4+ T cell counts that remained greater than pretherapy baseline levels, at least through 96 weeks of

25 decreased RXR-alpha expression compared with pretherapy bexarotene-sensitive cells.

26 Four coded sections from each of 20 pretherapy biopsies and each of 20 posttherapy biopsies

27 Pretherapy biopsy specimens were available for 265 of 50

28 Responders had lower pretherapy blasts (P =.016), a lower duration of prether

29 te neutropenia, which occurred regardless of pretherapy blood counts, and persisted an average of 2 m

30 The pretherapy blood dosimetry protocol can be substantially

31 r biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, co

32 d had a higher percentage of blasts in their pretherapy bone marrow than patients who completed 12 we

33 Pretherapy Cbl, MMA, and HCys values in individual patie

34 In these patients, pretherapy Cbl, MMA, and HCys values were normal in 54%,

35 plication and that STI was largely restoring pretherapy CD8(+) T cell responses in patients with esta

36 Disease stage was the only pretherapy clinical variable associated with outcome (P=

37 tic efficiency, 10-fold when compared to the pretherapy clone LAI.

38 ne patients with fibrolamellar HCC underwent pretherapy computed tomography (CT); 11 underwent prethe

39 ree of response compared with dosimetry from pretherapy conjugate views alone.

40 Dosimetry based on a combination of pretherapy conjugate views and intratherapy SPECT provid

41 ompared with the same statistic estimated by pretherapy conjugate views.

42 Daily pretherapy conjugate-view images provided the shape of t

43 17 patients who had extrahepatic disease at pretherapy CT and in four of the seven patients who seem

44 istogram analysis of the primary mass on the pretherapy CT images were performed by using TexRAD soft

45 Furthermore, pretherapy CT-derived properties correlate with clinical

46 mum diameter of the lesion was recorded on a pretherapy diagnostic CT scan or on the CT component of

47 l compliance exceeded 70% for structural and pretherapy disease assessment indicators but was lower f

48 patients who received chemotherapy had fewer pretherapy events than younger patients and were less li

49 itors when AR-V7-positive CTCs were detected pretherapy (hazard ratio, 0.24; 95% CI, 0.10-0.57; P = .

50 iance within the full viral coding region of pretherapy HCV sequences from 94 participants in the Vir

51 Pretherapy hepatic HCV-RNA concentrations correlated bes

52 Pretherapy HIV-1 RNA levels were prognostic independentl

53 spread, nine (29%) had distant metastases on pretherapy images, and 20 (65%) had lymphadenopathy.

54 Patients received a pretherapy imaging study with (111)In-DOTA-epratuzumab I

55 uccess was predefined as a 50% increase over pretherapy in estimated annual rate of weight gain, or c

56 ere we report that a virus, generated from a pretherapy isolate from the same patient, engineered to

57 on of the level of HIV-1 RNA did not vary by pretherapy level.

58 suppression recovered rapidly and surpassed pretherapy levels by day 7 after treatment, resulting in

59 e maintenance of plasma HIV RNA levels below pretherapy levels.

60 In these subjects, pretherapy LV SUV was markedly lower with respect to the

61 erapy computed tomography (CT); 11 underwent pretherapy magnetic resonance (MR) imaging.

62 of swallowing were only slightly worse than pretherapy measures, representing potential improvement

63 We analyzed pretherapy MN1 expression in 140 older (>/= 60 years) de

64 Objective: To determine if pretherapy nuclear androgen-receptor splice variant 7 (A

65 eal for staging patients, monitoring disease pretherapy or posttherapy, and especially for evaluating

66 The pretherapy PET data were used to segment BM volumes and

67 The pretherapy PET data were used to segment the lesion volu

68 Pretherapy planning and posttreatment response assessmen

69 herapy blasts (P =.016), a lower duration of pretherapy platelet transfusions (P =.013), and higher p

70 platelet transfusions (P =.013), and higher pretherapy platelets (P =.003).

71 The pretherapy population was composed of 22 Ta, 57 Tis, and

72 scriptase genotype was unrelated to outcome, pretherapy protease genotype was related significantly t

73 Pretherapy PSA, AJCC clinical stage, and biopsy Gleason

74 We demonstrate that pretherapy pulmonary function, pathologic and radiograph

75 Thirty-eight of 196 (19%) patients without pretherapy resistance evolved resistance to 1 or more dr

76 Overall, 16 of 212 (8%) patients had pretherapy resistance.

77 Initially, the assay was optimized in pretherapy samples from 20 adults with AML whose leukemi

78 Prediction analysis using pretherapy samples identified 79 genes that correctly cl

79 Pretherapy samples taken from patients that achieved CR

80 ntive strategies, questioning the utility of pretherapy screening computed tomography scans and masks

81 an enlarged binding cavity when compared to pretherapy structures in the Protein Data Bank.

82 SUV were also divided into tertiles based on pretherapy SUV to investigate differences in the relativ

83 Pretherapy SUV(max) and SUV(mean) and posttherapy SUV(ma

84 There was a weak correlation with pretherapy SUVmax and Ki-67 (r = 0.29, P = 0.04), but th

85 particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict t

86 From pretherapy to 12 months post-therapy, the Swallowing and

87 FEV1, and FEF25-75 across the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9

88 Analysis of pretherapy tumors demonstrated that advanced primary tum

89 pyuria and no alternative diagnosis) UTI on pretherapy urinalysis and culture.

90 icated cystitis, empirical therapy without a pretherapy urine culture is often used.

91 Accordingly, pretherapy urine isolates from 65 men with FUTI were com

92 reas mean CD4+ T-cell number was only 35% of pretherapy values (P < .05).

93 in lymphocytes in all patients, relative to pretherapy values.

94 ry rates in the absence of drug, relative to pretherapy VCV-sensitive isolates.

95 ART, viral diversity was not different from pretherapy viral diversity despite more than 10,000-fold

96 The level of pretherapy viremia extrapolated for each phase of decay

97 lure in the animal with the highest level of pretherapy viremia.

98 s the day (7:00 A.M. pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versu

99 es where the posttherapy NAFX is higher than pretherapy) was even broader.

100 d annual rate of weight gain, or change from pretherapy weight loss to statistically significant on-s